de Bie Katelijne C C, Veerman Hans, Bodar Yves J L, Meijer Dennie, van Leeuwen Pim J, van der Poel Henk G, Donswijk Maarten L, Vis André N, Oprea-Lager Daniela E
Department of Urology, VU University, Amsterdam University Medical Centers, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Department of Radiology & Nuclear Medicine, VU University, Amsterdam University Medical Centers, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Diagnostics (Basel). 2023 Jul 11;13(14):2343. doi: 10.3390/diagnostics13142343.
This study aimed to investigate the association between the Ga- or F-radiolabeled prostate-specific membrane antigen (PSMA) tracer expression, represented by the maximum standardised uptake value (SUV) of the dominant intraprostatic lesion, and biochemical recurrence (BCR) in primary prostate cancer (PCa) patients prior to robot-assisted radical prostatectomy (RARP). This was a retrospective, multi-centre cohort study of 446 patients who underwent [Ga]Ga-PSMA-11 ( = 238) or [F]DCFPyL ( = 206) Positron Emission Tomography/Computed Tomography (PET/CT) imaging prior to RARP. SUV was measured in the dominant intraprostatic PCa lesions. [F]DCFPyL patients were scanned 60 ([F]DCFPyL-60; = 106) or 120 ([F]DCFPyL-120; = 120) minutes post-injection of a radiotracer and were analysed separately. To normalise the data, SUV was log transformed for further analyses. During a median follow-up of 24 months, 141 (30.4%) patients experienced BCR. LogSUV was a significant predictor for BCR ( < 0.001). In the multivariable analysis accounting for these preoperative variables: initial prostate-specific antigen (PSA), radiologic tumour stage (mT), the biopsy International Society of Urological Pathology grade group (bISUP) and the prostate imaging and reporting data system (PI-RADS), LogSUV was found to be an independent predictor for BCR in [Ga]Ga-PSMA-11 (HR 1.32, 0.04) and [F]DCFPyL-120 PET/CT scans (HR 1.55, 0.04), but not in [F]DCFPyL-60 ones (HR 0.92, 0.72). The PSMA expression of the dominant intraprostatic lesion proved to be an independent predictor for BCR in patients with primary PCa who underwent [Ga]Ga-PSMA-11 or [F]DCFPyL-120 PET/CT scans, but not in those who underwent [F]DCFPyL-60 PET/CT scans.
本研究旨在调查在机器人辅助根治性前列腺切除术(RARP)前,以前列腺内主要病灶的最大标准化摄取值(SUV)表示的镓或氟放射性标记的前列腺特异性膜抗原(PSMA)示踪剂表达与原发性前列腺癌(PCa)患者生化复发(BCR)之间的关联。这是一项回顾性、多中心队列研究,纳入了446例在RARP前接受[Ga]Ga-PSMA-11(n = 238)或[F]DCFPyL(n = 206)正电子发射断层扫描/计算机断层扫描(PET/CT)成像的患者。在前列腺内主要的PCa病灶中测量SUV。[F]DCFPyL组患者在注射放射性示踪剂后60分钟([F]DCFPyL-60;n = 106)或120分钟([F]DCFPyL-12;n = 120)进行扫描,并分别进行分析。为了使数据标准化,对SUV进行对数转换以进行进一步分析。在中位随访24个月期间,141例(30.4%)患者出现BCR。LogSUV是BCR的显著预测因子(P < 0.001)。在考虑这些术前变量的多变量分析中:初始前列腺特异性抗原(PSA)、放射学肿瘤分期(mT)、活检国际泌尿病理学会分级组(bISUP)和前列腺影像报告和数据系统(PI-RADS),发现LogSUV是[Ga]Ga-PSMA-11(HR 1.32,P = 0.04)和[F]DCFPyL-120 PET/CT扫描(HR 1.55,P = 0.04)中BCR的独立预测因子,但在[F]DCFPyL-60扫描中不是(HR 0.92,P = 0.72)。前列腺内主要病灶的PSMA表达被证明是接受[Ga]Ga-PSMA-11或[F]DCFPyL-120 PET/CT扫描的原发性PCa患者BCR的独立预测因子,但在接受[F]DCFPyL-60 PET/CT扫描的患者中不是。